Jazz Pharmaceuticals (JAZZ) Competitors

Royalty Pharma (NASDAQ:RPRX) and Jazz Pharmaceuticals (NASDAQ:JAZZ) are both finance companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, valuation, risk, dividends, earnings, analyst recommendations, institutional ownership, community ranking and media sentiment.

Do analysts recommend RPRX or JAZZ?

Royalty Pharma currently has a consensus price target of $41.67, indicating a potential upside of 67.20%. Jazz Pharmaceuticals has a consensus price target of $177.00, indicating a potential upside of 43.94%. Given Royalty Pharma's higher possible upside, equities research analysts clearly believe Royalty Pharma is more favorable than Jazz Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Royalty Pharma	0 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.83
Jazz Pharmaceuticals	0 Sell rating(s)	2 Hold rating(s)	13 Buy rating(s)	0 Strong Buy rating(s)	2.87

Does the media favor RPRX or JAZZ?

In the previous week, Jazz Pharmaceuticals had 7 more articles in the media than Royalty Pharma. MarketBeat recorded 14 mentions for Jazz Pharmaceuticals and 7 mentions for Royalty Pharma. Royalty Pharma's average media sentiment score of 0.68 beat Jazz Pharmaceuticals' score of 0.15 indicating that Royalty Pharma is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Royalty Pharma	4 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive
Jazz Pharmaceuticals	3 Very Positive mention(s)	1 Positive mention(s)	9 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Do insiders & institutionals believe in RPRX or JAZZ?

54.3% of Royalty Pharma shares are owned by institutional investors. Comparatively, 89.1% of Jazz Pharmaceuticals shares are owned by institutional investors. 18.9% of Royalty Pharma shares are owned by company insiders. Comparatively, 4.2% of Jazz Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Does the MarketBeat Community prefer RPRX or JAZZ?

Jazz Pharmaceuticals received 802 more outperform votes than Royalty Pharma when rated by MarketBeat users. Likewise, 80.76% of users gave Jazz Pharmaceuticals an outperform vote while only 67.86% of users gave Royalty Pharma an outperform vote.

Company	Underperform	Outperform
Royalty Pharma	Outperform Votes 323 67.86%	Underperform Votes 153 32.14%
Jazz Pharmaceuticals	Outperform Votes 1125 80.76%	Underperform Votes 268 19.24%

Which has more risk and volatility, RPRX or JAZZ?

Royalty Pharma has a beta of 0.46, meaning that its share price is 54% less volatile than the S&P 500. Comparatively, Jazz Pharmaceuticals has a beta of 0.57, meaning that its share price is 43% less volatile than the S&P 500.

Which has stronger valuation and earnings, RPRX or JAZZ?

Royalty Pharma has higher earnings, but lower revenue than Jazz Pharmaceuticals. Royalty Pharma is trading at a lower price-to-earnings ratio than Jazz Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Royalty Pharma	$2.27B	6.48	$1.13B	$1.93	12.91
Jazz Pharmaceuticals	$3.99B	1.86	$414.83M	$7.10	17.32

Is RPRX or JAZZ more profitable?

Royalty Pharma has a net margin of 50.53% compared to Jazz Pharmaceuticals' net margin of 11.60%. Jazz Pharmaceuticals' return on equity of 29.30% beat Royalty Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Royalty Pharma	50.53%	24.65%	14.44%
Jazz Pharmaceuticals	11.60%	29.30%	9.72%

Summary

Jazz Pharmaceuticals beats Royalty Pharma on 11 of the 18 factors compared between the two stocks.